Literature DB >> 16943475

Treatment of aneurysmal bone cysts with percutaneous sclerotherapy using polidocanol. A review of 72 cases with long-term follow-up.

S Rastogi1, M K Varshney, V Trikha, S A Khan, B Choudhury, R Safaya.   

Abstract

Aneurysmal bone cyst is a rare tumour-like lesion which develops during growth. Our aim was to determine the efficacy of the administration of percutaneous intralesional 3% polidocanol (hydroxypolyaethoxydodecan) as sclerotherapy. Between July 1997 and December 2004 we treated 72 patients (46 males, 26 females) with a histologically-proven diagnosis of aneurysmal bone cyst, at various skeletal sites using this method. The sclerotherapy was performed under fluoroscopic guidance and general anaesthesia or sedation and local anaesthesia. The mean follow-up period was 34 months (26.5 to 80). The patients were evaluated using the Enneking system for functional assessment and all the lesions were radiologically quantified into four grades. The mean age of patients was 15.6 years (3 to 38) and the mean number of injections was three (1 to 5). Ten patients were cured by a single injection. The mean reduction in size of the lesion (radiological healing) was found to be 76.6% (61.9% to 93.2%) with a mean clinical response of 84.5% (73.4% to 100%). Recurrence was seen in two patients (2.8%) within two years of treatment and both were treated successfully by further sclerotherapy. Percutaneous sclerotherapy with polidocanol is a safe alternative to conventional surgery for the treatment of an aneurysmal bone cyst. It can be used at surgically-inaccessible sites and treatment can be performed on an out-patient basis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943475     DOI: 10.1302/0301-620X.88B9.17829

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  44 in total

Review 1.  [New surgical treatment options for bone tumors].

Authors:  D Andreou; M P Henrichs; G Gosheger; M Nottrott; A Streitbürger; J Hardes
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

Review 2.  Paediatric musculoskeletal interventional radiology.

Authors:  Gian L Natali; Guglielmo Paolantonio; Rodolfo Fruhwirth; Giuseppe Alvaro; George K Parapatt; Paolo Toma'; Massimo Rollo
Journal:  Br J Radiol       Date:  2015-09-23       Impact factor: 3.039

3.  [Percutaneous sclerotherapy with polidocanol : Successful relapse therapy of infantile aneurysmal bone cyst].

Authors:  S Rieger; J Dickschas
Journal:  Unfallchirurg       Date:  2016-09       Impact factor: 1.000

4.  "Soap bubble" in the calcaneus.

Authors:  Suma Kuna; Ravindra Gudena
Journal:  CMAJ       Date:  2011-05-16       Impact factor: 8.262

5.  Aneurysmal bone cyst of medial cuneiform and a novel surgical technique for mid-foot reconstruction.

Authors:  Venkatesan Sampath Kumar; Divesh Jalan; Shah Alam Khan; Asit Ranjan Mridha
Journal:  BMJ Case Rep       Date:  2014-02-21

6.  [Bone cysts-differential diagnosis and therapeutic approach].

Authors:  Markus Weber; Axel Hillmann
Journal:  Orthopade       Date:  2018-07       Impact factor: 1.087

7.  Qualitative evaluation of MRI features in aneurysmal bone cysts after percutaneous sclerotherapy.

Authors:  Eric S Bih; Kimberly Dao; Horacio Padua; Raja Shaikh
Journal:  Skeletal Radiol       Date:  2020-09-15       Impact factor: 2.199

8.  Treatment of the aneurysmal bone cyst by percutaneous intracystic sclerotherapy using ethanol ninety five percent in children.

Authors:  Alexandru Ulici; Daniel-Catalin Florea; Madalina Carp; Alin Ladaru; Iulia Tevanov
Journal:  Int Orthop       Date:  2018-02-28       Impact factor: 3.075

9.  Aneurysmal bone cyst of the metatarsal: A case report.

Authors:  Jiangyinzi Shang; Runsheng Guo; Ping Zhan; Chuwen Chen; Jing Kan; Hucheng Liu; Min Dai
Journal:  Oncol Lett       Date:  2016-08-12       Impact factor: 2.967

10.  Percutaneous doxycycline treatment of aneurysmal bone cysts with low recurrence rate: a preliminary report.

Authors:  William E Shiels; Joel L Mayerson
Journal:  Clin Orthop Relat Res       Date:  2013-05-14       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.